​
​

Celularity (CELU) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

CELU Stock Forecast

Celularity stock forecast is as follows: an average price target of $6.00 (represents a 110.53% upside from CELU’s last price of $2.85) and a rating consensus of 'Hold', based on 2 wall street analysts offering a 1-year stock forecast.

CELU Price Target

The average price target for Celularity (CELU) is $6.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 110.53% upside from CELU's last price of $2.85.

CELU Analyst Ratings

Hold

According to 2 Wall Street analysts, Celularity's rating consensus is 'Hold'. The analyst rating breakdown for CELU stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 2 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Celularity Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 23, 2022Asthika GoonewardeneTruist Financial$6.00$2.79115.05%110.53%
Row per page
Go to

The latest Celularity stock forecast, released on Aug 23, 2022 by Asthika Goonewardene from Truist Financial, set a price target of $6.00, which represents a 115.05% increase from the stock price at the time of the forecast ($2.79), and a 110.53% increase from CELU last price ($2.85).

Celularity Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$2.85$2.85$2.85
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Celularity stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Celularity's last price of $2.85. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Sep 12, 2022Morgan StanleyEqual-WeightEqual-WeightHold
Apr 26, 2022Truist Financial-HoldDowngrade
Row per page
Go to

Celularity's last stock rating was published by Morgan Stanley on Sep 12, 2022. The company gave CELU a "Equal-Weight" rating, the same as its previous rate.

Celularity Financial Forecast

Celularity Revenue Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21
Revenue-----$3.79M-$3.94M$4.13M--$5.93M$4.86M-
Avg Forecast$5.20M$5.30M$4.80M$4.40M$4.71M$27.22M$26.80M$6.90M$5.49M$5.74M$5.44M$5.09M$4.58M$1.73M
High Forecast$5.20M$5.30M$4.80M$4.40M$4.71M$27.22M$26.80M$6.90M$5.49M$5.74M$5.44M$5.09M$4.58M$1.73M
Low Forecast$5.20M$5.30M$4.80M$4.40M$4.71M$27.22M$26.80M$6.90M$5.49M$5.74M$5.44M$5.09M$4.58M$1.73M
# Analysts11111111111111
Surprise %-----0.14%-0.57%0.75%--1.17%1.06%-

Celularity's average Quarter revenue forecast for Dec 23 based on 1 analysts is $4.71M, with a low forecast of $4.71M, and a high forecast of $4.71M. CELU's average Quarter revenue forecast represents a 24.35% increase compared to the company's last Quarter revenue of $3.79M (Sep 23).

Celularity EBITDA Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21
# Analysts11111111111111
EBITDA-----$-99.26M-$-52.41M$-32.84M--$-34.80M$-655.00K-
Avg Forecast$-2.16M$-2.20M$-2.00M$-1.83M$-1.96M$-11.32M$-11.15M$-2.87M$-2.28M$-4.68M$-4.44M$-50.45M$-3.74M$-1.41M
High Forecast$-2.16M$-2.20M$-2.00M$-1.83M$-1.96M$-11.32M$-11.15M$-2.87M$-2.28M$-4.68M$-4.44M$-40.36M$-3.74M$-1.41M
Low Forecast$-2.16M$-2.20M$-2.00M$-1.83M$-1.96M$-11.32M$-11.15M$-2.87M$-2.28M$-4.68M$-4.44M$-60.54M$-3.74M$-1.41M
Surprise %-----8.77%-18.26%14.39%--0.69%0.18%-

undefined analysts predict CELU's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Celularity's previous annual EBITDA (undefined) of $NaN.

Celularity Net Income Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21
# Analysts11111111111111
Net Income-----$-93.88M-$-64.44M$24.43M--$-88.97M$-4.04M-
Avg Forecast$-32.77M$-30.59M$-30.59M$-30.59M$45.63M$-6.55M$-6.55M$-52.44M$-55.50M$-56.10B$-56.01B$-52.35M$-66.60B$-73.97B
High Forecast$-32.77M$-30.59M$-30.59M$-30.59M$45.63M$-6.55M$-6.55M$-52.44M$-55.50M$-56.10B$-56.01B$-41.88M$-66.60B$-73.97B
Low Forecast$-32.77M$-30.59M$-30.59M$-30.59M$45.63M$-6.55M$-6.55M$-52.44M$-55.50M$-56.10B$-56.01B$-62.82M$-66.60B$-73.97B
Surprise %-----14.32%-1.23%-0.44%--1.70%0.00%-

Celularity's average Quarter net income forecast for Mar 23 is $-52.44M, with a range of $-52.44M to $-52.44M. CELU's average Quarter net income forecast represents a -314.62% decrease compared to the company's last Quarter net income of $24.43M (Dec 22).

Celularity SG&A Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21
# Analysts11111111111111
SG&A-----$10.75M-$13.93M$19.08M--$16.46M$13.21M-
Avg Forecast$11.97M$12.20M$11.05M$10.13M$10.84M$62.68M$61.70M$15.89M$12.63M$13.22M$12.52M$11.72M$10.55M$3.98M
High Forecast$11.97M$12.20M$11.05M$10.13M$10.84M$62.68M$61.70M$15.89M$12.63M$13.22M$12.52M$11.72M$10.55M$3.98M
Low Forecast$11.97M$12.20M$11.05M$10.13M$10.84M$62.68M$61.70M$15.89M$12.63M$13.22M$12.52M$11.72M$10.55M$3.98M
Surprise %-----0.17%-0.88%1.51%--1.40%1.25%-

Celularity's average Quarter SG&A projection for Dec 23 is $10.84M, based on 1 Wall Street analysts, with a range of $10.84M to $10.84M. The forecast indicates a 0.85% rise compared to CELU last annual SG&A of $10.75M (Sep 23).

Celularity EPS Forecast

Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21
# Analysts11111111111111
EPS-----$-0.00-$-0.41$0.31--$-0.68$-0.03-
Avg Forecast$-1.50$-1.40$-1.40$-1.40$2.09$-0.30$-0.30$-2.40$-2.54$-2.62$-2.61$-2.27$-3.11$-3.45
High Forecast$-1.50$-1.40$-1.40$-1.40$2.09$-0.30$-0.30$-2.40$-2.54$-2.62$-2.61$-2.27$-3.11$-3.45
Low Forecast$-1.50$-1.40$-1.40$-1.40$2.09$-0.30$-0.30$-2.40$-2.54$-2.62$-2.61$-2.27$-3.11$-3.45
Surprise %-----0.00%-0.17%-0.12%--0.30%0.01%-

According to 1 Wall Street analysts, Celularity's projected average Quarter EPS for Mar 23 is $-2.40, with a low estimate of $-2.40 and a high estimate of $-2.40. This represents a -874.19% decrease compared to CELU previous annual EPS of $0.31 (Dec 22).

Celularity Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.69$70.0010044.93%Buy
IMMXImmix Biopharma$1.68$7.00316.67%Buy
CNSPCNS Pharmaceuticals$0.13$0.50284.62%-
CELUCelularity$2.85$6.00110.53%Hold
VECTVectivBio$16.87$18.006.70%Buy
EFTReFFECTOR Therapeutics-$5.50-Buy

CELU Forecast FAQ

Is Celularity a good buy?

No, according to 2 Wall Street analysts, Celularity (CELU) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of CELU's total ratings.

What is CELU's price target?

Celularity (CELU) average price target is $6 with a range of $6 to $6, implying a 110.53% from its last price of $2.85. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Celularity stock go up soon?

According to Wall Street analysts' prediction for CELU stock, the company can go up by 110.53% (from the last price of $2.85 to the average price target of $6), up by 110.53% based on the highest stock price target, and up by 110.53% based on the lowest stock price target.

Can Celularity stock reach $4?

CELU's average twelve months analyst stock price target of $6 supports the claim that Celularity can reach $4 in the near future.

What are Celularity's analysts' financial forecasts?

Celularity's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $65.63M (high $65.63M, low $65.63M), average EBITDA is $-27.297M (high $-27.297M, low $-27.297M), average net income is $-19.918M (high $-19.918M, low $-19.918M), average SG&A $151.11M (high $151.11M, low $151.11M), and average EPS is $-0.912 (high $-0.912, low $-0.912). CELU's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $19.7M (high $19.7M, low $19.7M), average EBITDA is $-8.194M (high $-8.194M, low $-8.194M), average net income is $-125M (high $-125M, low $-125M), average SG&A $45.36M (high $45.36M, low $45.36M), and average EPS is $-5.7 (high $-5.7, low $-5.7).

Did the CELU's actual financial results beat the analysts' financial forecasts?

Based on Celularity's last annual report (Dec 2022), the company's revenue was $17.98M, which missed the average analysts forecast of $21.76M by -17.38%. Apple's EBITDA was $-141M, beating the average prediction of $-61.855M by 128.17%. The company's net income was $14.19M, missing the average estimation of $-112B by -100.01%. Apple's SG&A was $66.02M, beating the average forecast of $50.09M by 31.80%. Lastly, the company's EPS was $0.0001, missing the average prediction of $-10.036 by -100.00%. In terms of the last quarterly report (Sep 2023), Celularity's revenue was $3.79M, missing the average analysts' forecast of $27.22M by -86.09%. The company's EBITDA was $-99.256M, beating the average prediction of $-11.323M by 776.61%. Celularity's net income was $-93.876M, beating the average estimation of $-6.555M by 1332.14%. The company's SG&A was $10.75M, missing the average forecast of $62.68M by -82.85%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.3 by -99.83%